ReviewVascular health and risk management2007
Review of bosentan in the management of pulmonary arterial hypertension.
Review in Vascular health and risk management, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Pharmacology Management in Improving Exercise Capacity of Patients with Fontan Circulation: A Systematic Review and Meta-analysis.Current cardiology reviews · 2022Pooled it
- Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021Pooled it
- Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.Journal of the American Heart Association · 2016Pooled it
- Pooled it
- Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects.British journal of clinical pharmacology · 2012Trial
- Preparation of orodispersible tablets of bosentan using xylitol and menthol as dissolution enhancers.Scientific reports · 2024Article
- Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?Nephrology (Carlton, Vic.) · 2023Review
- Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2022Review
- Inhibitor of differentiation 1 in U87MG glioblastoma cells promotes HUVEC sprouting through endothelin-1.Oncology letters · 2022Article
- Bosentan-induced immune hemolytic anemia in 17 years old man. A case report.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2021Article
- Enigma of pulmonary hypertension; echocardiography in the crossroads.Respiratory medicine case reports · 2020Article
- Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update.Drug, healthcare and patient safety · 2019Article
- State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.Clinical pharmacokinetics · 2019Review
- Stability of an Extemporaneously Compounded Oral Suspension of Bosentan.Hospital pharmacy · 2016Article
- Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension.Drug design, development and therapy · 2016Review
- Role of endothelin receptor antagonist; bosentan in cisplatin-induced nephrotoxicity in ovariectomized estradiol treated rats.Journal of nephropathology · 2015Article
- Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.Drug safety · 2015Review
- Activation of hypoxia-inducible factor-1 in pulmonary arterial smooth muscle cells by endothelin-1.American journal of physiology. Lung cellular and molecular physiology · 2013Article
- Bosentan monohydrate.Acta crystallographica. Section E, Structure reports online · 2013Article
- Changes of gene expression after bone marrow cell transfusion in rats with monocrotaline-induced pulmonary hypertension.Journal of Korean medical science · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which is effective in the treatment of pulmonary arterial hypertension (PAH). This review critically appraises the evidence for the efficacy of bosentan in idiopathic and familial PAH, in PAH associated with connective tissue disease and in PAH which may develop in association with other conditions. Data from the pivotal placebo controlled studies and their open labeled extensions as well as long term survival and quality of life data is presented. Data is also presented on the potential benefit of bosentan in patients with inoperable chronic thromboembolic pulmonary hypertension. The safety and tolerability of bosentan as well as drug interactions are discussed. Dosage recommendations in adults and pediatrics are presented. An algorithm is provided to guide the reader in monitoring potential increases in alanine and aspartate transaminase levels that may occur with bosentan use and the dose adjustments that are recommended as a result of any increase in the levels of these enzymes are shown. Finally, the role of bosentan as part of combination therapy in PAH is examined.
Indexed as
Identifiers
18200808PMC2350123W1517782830What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.